Cool_老虎社区_美港股上老虎

SiewWeng
2021-09-23

Cool

Novavax surged over 10% in early trading<blockquote>Novavax早盘大涨超10%</blockquote>

(Sept 23) Novavax surged over 10% in early trading. Novavax Announce Submission to World Health Orga

Novavax surged over 10% in early trading<blockquote>Novavax早盘大涨超10%</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":863570197,"tweetId":"863570197","gmtCreate":1632408617419,"gmtModify":1632730940117,"author":{"id":3585252654864862,"idStr":"3585252654864862","authorId":3585252654864862,"authorIdStr":"3585252654864862","name":"SiewWeng","avatar":"https://static.tigerbbs.com/53df5a10f848dd9d79558c4f7a3fb9f8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Cool</p></body></html>","htmlText":"<html><head></head><body><p>Cool</p></body></html>","text":"Cool","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/863570197","repostId":1136461867,"repostType":4,"repost":{"id":"1136461867","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1632405237,"share":"https://www.laohu8.com/m/news/1136461867?lang=zh_CN&edition=full","pubTime":"2021-09-23 21:53","market":"other","language":"en","title":"Novavax surged over 10% in early trading<blockquote>Novavax早盘大涨超10%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1136461867","media":"Tiger Newspress","summary":"(Sept 23) Novavax surged over 10% in early trading. Novavax Announce Submission to World Health Orga","content":"<p>(Sept 23)&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> </b>surged over 10% in early trading.&nbsp;Novavax Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine.</p><p><blockquote>（9月23日）<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>早盘大涨超10%Novavax宣布向世界卫生组织提交Novavax新冠疫苗紧急使用清单。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/38fe74a02950ee20c0a498be55a8e0a4\" tg-width=\"958\" tg-height=\"563\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd. (SII), today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant. The submission to WHO is based on the companies' previous regulatory submission to the Drugs Controller General ofIndia(DCGI).</p><p><blockquote>Novavax，Inc.（纳斯达克代码：NVAX）是一家致力于开发和商业化用于严重传染病的下一代疫苗的生物技术公司，其合作伙伴Serum Institute of India Pvt.Ltd.（SII）今天宣布向世界卫生组织（WHO）提交一份监管文件，将Novavax的基于重组纳米颗粒蛋白和Matrix-M的COVID-19候选疫苗列入紧急使用清单（EUL）™佐剂。向世卫组织提交的文件是基于这些公司之前向印度药品总监(DCGI)提交的监管文件。</blockquote></p><p> \"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelerating access and more equitable distribution to countries in great need around the world,\" saidStanley C. Erck, President and Chief Executive Officer, Novavax. \"It represents another major milestone in Novavax' transformation into a commercial global vaccine company and reinforces the value of global collaboration and need for multiple approaches to help control the pandemic.\"</p><p><blockquote>总裁兼首席执行官斯坦利·C·埃尔克(Stanley C.Erck)表示：“今天，我们向世界卫生组织提交了基于蛋白质的COVID-19疫苗以供紧急使用，这是加快向世界各地急需的国家获取和更公平分配的重要一步。”Novavax执行官。“这代表了Novavax向商业全球疫苗公司转型的另一个重要里程碑，并强化了全球合作的价值以及对多种方法帮助控制大流行的需求。”</blockquote></p><p> The grant of EUL by the WHO is a prerequisite for exports to numerous countries participating in the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. In addition to the submission for WHO EUL, SII and Novavax last month completed the submission of modules required by regulatory agencies inIndia,Indonesiaandthe Philippinesfor the initiation of review of the vaccine, including preclinical, clinical, and chemistry, manufacturing and controls (CMC) data.</p><p><blockquote>世卫组织授予EUL是向许多参与新冠疫苗保障机制的国家出口的先决条件，该组织的成立是为了向参与国和经济体公平分配和分发疫苗。除了向WHO EUL提交外，SII和Novavax上个月还完成了印度、印度尼西亚和菲律宾监管机构要求的模块的提交，以启动疫苗审查，包括临床前、临床以及化学、制造和控制(CMC)数据。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax surged over 10% in early trading<blockquote>Novavax早盘大涨超10%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax surged over 10% in early trading<blockquote>Novavax早盘大涨超10%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-09-23 21:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Sept 23)&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a> </b>surged over 10% in early trading.&nbsp;Novavax Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine.</p><p><blockquote>（9月23日）<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>早盘大涨超10%Novavax宣布向世界卫生组织提交Novavax新冠疫苗紧急使用清单。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/38fe74a02950ee20c0a498be55a8e0a4\" tg-width=\"958\" tg-height=\"563\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd. (SII), today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant. The submission to WHO is based on the companies' previous regulatory submission to the Drugs Controller General ofIndia(DCGI).</p><p><blockquote>Novavax，Inc.（纳斯达克代码：NVAX）是一家致力于开发和商业化用于严重传染病的下一代疫苗的生物技术公司，其合作伙伴Serum Institute of India Pvt.Ltd.（SII）今天宣布向世界卫生组织（WHO）提交一份监管文件，将Novavax的基于重组纳米颗粒蛋白和Matrix-M的COVID-19候选疫苗列入紧急使用清单（EUL）™佐剂。向世卫组织提交的文件是基于这些公司之前向印度药品总监(DCGI)提交的监管文件。</blockquote></p><p> \"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelerating access and more equitable distribution to countries in great need around the world,\" saidStanley C. Erck, President and Chief Executive Officer, Novavax. \"It represents another major milestone in Novavax' transformation into a commercial global vaccine company and reinforces the value of global collaboration and need for multiple approaches to help control the pandemic.\"</p><p><blockquote>总裁兼首席执行官斯坦利·C·埃尔克(Stanley C.Erck)表示：“今天，我们向世界卫生组织提交了基于蛋白质的COVID-19疫苗以供紧急使用，这是加快向世界各地急需的国家获取和更公平分配的重要一步。”Novavax执行官。“这代表了Novavax向商业全球疫苗公司转型的另一个重要里程碑，并强化了全球合作的价值以及对多种方法帮助控制大流行的需求。”</blockquote></p><p> The grant of EUL by the WHO is a prerequisite for exports to numerous countries participating in the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. In addition to the submission for WHO EUL, SII and Novavax last month completed the submission of modules required by regulatory agencies inIndia,Indonesiaandthe Philippinesfor the initiation of review of the vaccine, including preclinical, clinical, and chemistry, manufacturing and controls (CMC) data.</p><p><blockquote>世卫组织授予EUL是向许多参与新冠疫苗保障机制的国家出口的先决条件，该组织的成立是为了向参与国和经济体公平分配和分发疫苗。除了向WHO EUL提交外，SII和Novavax上个月还完成了印度、印度尼西亚和菲律宾监管机构要求的模块的提交，以启动疫苗审查，包括临床前、临床以及化学、制造和控制(CMC)数据。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136461867","content_text":"(Sept 23) Novavax surged over 10% in early trading. Novavax Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine.\n\nNovavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd. (SII), today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant. The submission to WHO is based on the companies' previous regulatory submission to the Drugs Controller General ofIndia(DCGI).\n\"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelerating access and more equitable distribution to countries in great need around the world,\" saidStanley C. Erck, President and Chief Executive Officer, Novavax. \"It represents another major milestone in Novavax' transformation into a commercial global vaccine company and reinforces the value of global collaboration and need for multiple approaches to help control the pandemic.\"\nThe grant of EUL by the WHO is a prerequisite for exports to numerous countries participating in the COVAX Facility, which was established to allocate and distribute vaccines equitably to participating countries and economies. In addition to the submission for WHO EUL, SII and Novavax last month completed the submission of modules required by regulatory agencies inIndia,Indonesiaandthe Philippinesfor the initiation of review of the vaccine, including preclinical, clinical, and chemistry, manufacturing and controls (CMC) data.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1256,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}